The National Kidney Federation are aware that the National Institute for Health and Care Excellence (NICE) have published on 15th November 2022 a draft recommendation on the COVID-19 anti-viral treatments. The recommendations are to reduce the number of anti-viral treatments available for patients with COVID-19.

The draft recommendations are a cause for concern as many immunocompromised patients, including those with a reduced kidney function, do not have the most effective response to the COVID-19 vaccinations available.

A major treatment option that has been available as an anti-viral is Sotrovimab, and this looks to have been removed from the draft recommendation list. This treatment has had positive results within clinical trials and has proven to be effective. The National Kidney Federation will be keeping a close eye on NICE’s recommendation and hopes that they re-consider the draft recommendation to U-turn it’s withdrawal access to Sotrovimab.

To view the NICE draft recommendation visit:

To view our COVID-19 Support page visit:

If you have any queries about the above draft recommendation, we suggest to contact your kidney team.